ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0371

Lifestyle Coaching in Psoriatic Arthritis: Pilot Findings from an Online eCoaching Program

Judy Zhang1, Leonard Calabrese2, Shilpa Venkatachalam3, angela Degrassi4, Yuxuan Jin2 and M. Elaine Husni5, 1Cleveland Clinic, Cleveland, United States, Cleveland, OH, 2Cleveland Clinic, Cleveland, OH, 3Global Healthy Living Foundation, New York, NY, 4Global Healthy Living Foundation, Upper Nyack, NY, 5Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH

Meeting: ACR Convergence 2025

Keywords: education, patient, health behaviors, Patient reported outcomes, Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0357–0386) Patient Outcomes, Preferences, & Attitudes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: As healthcare shifts towards patient-centered care, multifactorial lifestyle interventions, though effective, often impose time and resource burdens on patients. An online program like IMMUNE STRENGTH can streamline delivery of mindfulness, sleep, nutrition and exercise support, reduce patient burden and enhancing self-management in psoriatic arthritis (PsA).

Methods: A prospective, single-arm pilot study evaluated the feasibility and preliminary efficacy of IMMUNE STRENGTH, a 10-week online, coach-led program targeting lifestyle interventions in adults (≥18 years) with PsA per ACR criteria. To enhance external validity, participants were recruited from an academic rheumatology clinic and a national patient advocacy group. Key exclusions included concomitant systemic autoimmune diseases and inability to engage in remote coaching.The program featured weekly modules focused on four core lifestyle pillars (mindfulness, sleep hygiene, nutrition, and exercise) delivered via a platform with videos, self-guided exercises, and tracking tools such as sleep logs and dietary journals. Certified health coaches led weekly communication and provided individualized support with emails or phone calls, delivering targeted education, answering questions, and gathering feedback in real time.Engagement was measured via module completion and coaching session attendance. Patient-reported outcomes were measured using validated PROMIS scales including pain, fatigue, and global health at baseline and post-intervention (Week 10). Feasibility was evaluated based on enrollment and retention rates. Continuous and categorical variables were described using means ± standard deviations and counts (%), respectively. Changes from baseline to Week 10 were analyzed using paired t-tests. All analyses were performed in R (v4.3.1), with a two-sided α = 0.05.

Results: Of the 143 enrolled, 86 (60.1%) completed the program and were included in the Week 10 analysis. PROMIS Global Mental Health T-scores rose from 42.2 to 44.7 (SD = 5.20, p < 0.001) and Global Physical Health T-scores from 39.1 to 41.1 (SD = 4.44, p = 0.001), approaching the 3-point minimal clinically important difference (MCID) commonly cited for PROMIS measures. Perceived stress, as measured by the 10-item Perceived Stress Scale (PSS-10), declined from 7.12 to 5.70 (SD = 3.04, p < 0.001). Self-efficacy also improved: symptom-management T-scores increased by 3.45 points (SD = 4.89, p < 0.001) and medication-management scores by 3.00 points (SD = 6.55, p < 0.001). Participants also experienced reductions in symptom burden, with fatigue scores falling from 60.4 to 57.2 (SD = 6.38, p < 0.001) and pain-interference scores from 61.8 to 58.5 (SD = 5.89, p < 0.001). Finally, 90.6% of completers reported being “satisfied” or “very satisfied,” and 87.5% would recommend IMMUNE STRENGTH to others.

Conclusion: The IMMUNE STRENGTH pilot showed significant improvements in mental and physical health, self-efficacy and symptom burden, supporting the potential of an online, coach-led lifestyle intervention as an adjunctive approach for managing PsA. Further research is needed to confirm these preliminary outcomes and evaluate long-term benefits.

Supporting image 1Change in PROMIS Global Mental and Physical Health and PSS 10 scores from baseline to post intervention

Supporting image 2Change in PROMIS Self Efficacy and Fatigue from baseline to post intervention.


Disclosures: J. Zhang: None; L. Calabrese: AbbVie, 2, Amgen, 2, 6, AstraZeneca, 2, 6, Bristol-Myers Squibb(BMS), 2, Fate Therapeutics, 2, Galvani, 2, Genentech, 2, GlaxoSmithKlein(GSK), 2, Janssen, 2, 6, Mymee, 2, Open Evidence, 2, PPD, 2, Regeneron, 2, 6, Sanofi-Genzyme, 2, 6, UCB, 2, 6; S. Venkatachalam: None; a. Degrassi: None; Y. Jin: None; M. Husni: AbbVie, 1, 2, Amgen, 1, 2, BMS, 1, 2, Eli Lilly, 1, 2, Janssen, 1, 2, Novartis, 1, 2, Pfizer, 1, 2, UCB, 1, 2.

To cite this abstract in AMA style:

Zhang J, Calabrese L, Venkatachalam S, Degrassi a, Jin Y, Husni M. Lifestyle Coaching in Psoriatic Arthritis: Pilot Findings from an Online eCoaching Program [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/lifestyle-coaching-in-psoriatic-arthritis-pilot-findings-from-an-online-ecoaching-program/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lifestyle-coaching-in-psoriatic-arthritis-pilot-findings-from-an-online-ecoaching-program/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology